Moderna Inc (MRNA) stock is lower by -21.86% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRNA stock a score of 73 out of a possible 100.
That rank is chiefly influenced by a fundamental score of 96. In addition to the average rating from Wall Street analysts, MRNA stock has a mean target price of $241.38. This means analysts expect the stock to increase 72.89% over the next 12 months. MRNA's rank also includes a short-term technical score of 64. The long-term technical score for MRNA is 58. MRNA has an Overall Score of 73. Find out what this means to you and get the rest of the rankings on MRNA!